Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease

Publisher： Karger

E-ISSN： 1421-9824|37|1-2|58-70

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.37, Iss.1-2, 2013-10, pp. : 58-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 4, Iss. 3, 2014-11 ,pp. : 450-456

Karger

Access to resources Recommend Favorite

Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month Period

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 4, 2005-03 ,pp. : 189-195

Karger

Access to resources Recommend Favorite

Parkinson’s Disease and CYP2D6 Polymorphism in Asian Populations: A Meta-Analysis

By  

Neuroepidemiology, Vol. 22, Iss. 6, 2003-10 ,pp. : 357-361

Karger

Access to resources Recommend Favorite

Polymorphism in the Cholesterol 24S-Hydroxylase Gene (CYP46A1) Associated with the APOEυ3 Allele Increases the Risk of Alzheimer’s Disease and of Mild Cognitive Impairment Progressing to Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 21, Iss. 2, 2006-01 ,pp. : 81-87

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite